Results 71 to 80 of about 23,087 (229)
Journal of Periodontal Research, EarlyView.This systematic review evaluated drug‐target Mendelian randomisation studies on periodontitis. Twelve studies identified host‐response‐related targets mainly involved in inflammatory, complement, and immune pathways. Although some targets were linked to existing drugs, the evidence remains preliminary and heterogeneous, requiring replication and ...
Luigi Nibali +4 more
wiley +1 more source
Denosumab: an investigational drug for the management of postmenopausal osteoporosis
, 2008 E Michael LewieckiNew Mexico Clinical Research & Osteoporosis Center, Albuquerque, New Mexico, USAAbstract: Denosumab (AMG 162) is an investigational fully human monoclonal antibody with a high affinity and specificity for receptor activator of ...
E Michael Lewiecki
core
Oral Diseases, EarlyView.ABSTRACT Background Identification of healthy bone margins is a critical step in the surgical resective treatment of medication‐related osteonecrosis of the jaw (MRONJ). Fluorescence‐guided surgery (FGS) has been proposed as a method to identify resection margins and improve clinical outcomes.
Paolo De Angelis +6 more
wiley +1 more source
Combined Effects of Romosozumab and Zoledronate on the Development of Osteonecrosis of the Jaw
Oral Diseases, EarlyView.ABSTRACT Objective This study aimed to assess the occurrence of medication‐related osteonecrosis of the jaw (MRONJ) in mice following the sequential administration of romosozumab and zoledronate and to confirm their inhibitory effects on osteoclast differentiation in vitro.
Hae‐Seo Park +5 more
wiley +1 more source
Denosumab for Male Hemodialysis Patients with Low Bone Mineral Density: A Case-Control Study
International Journal of Nephrology, 2017 Denosumab increases bone mineral density (BMD) in patients not receiving hemodialysis therapy. However, limited data are available in the literature concerning the use of denosumab in hemodialysis patients.
Hiroya Takami +2 more
doaj +1 more source
Effect of Denosumab on Bone Mineral Density of Hematopoietic Stem Cell Transplantation Recipients
International Journal of Endocrinology, 2020 Purpose. Denosumab is a monoclonal antibody that prevents the development of osteoclasts. The effect of denosumab in solid organ transplant recipients has been elucidated, but its effect in haematopoietic stem cell transplantation recipients has not been
Chaiho Jeong +4 more
doaj +1 more source
, 2017 Giant cell tumor (GCT) is a rare, usually benign but locally aggressive neoplasm. Recent studies suggest new approaches in light of the elucidation of molecular pathways in bone.
Mehmet Ali DevecI +3 more
core +1 more source
Oral Health Screening Prior to Oncological Treatment—The Helsinki Protocol
Oral Diseases, EarlyView.ABSTRACT Objectives Oncological treatments can have adverse effects on oral health and cause long‐term complications such as osteonecrosis. This retrospective study investigated the oral health of head and neck cancer patients before radiotherapy and patients with multiple myeloma, breast, prostate, lung, and kidney cancers before antiresorptive ...
Jemina Järvinen +4 more
wiley +1 more source
Biotechnology & Biotechnological EquipmentBulgarian real-world data on denosumab use for the prevention of skeletal-related events (SREs) associated with bone metastases (BM) from prostate cancer (PC) are lacking.
Antoaneta Tomova +4 more
doaj +1 more source
Case Reports in Oncological Medicine, 2018 Background. Denosumab has become the preferred agent over zolendronic acid to help prevent skeletal-related events in patients with metastatic bone disease and multiple myeloma because it is approved for use in those with kidney dysfunction.
Christina F. Marlow +3 more
doaj +1 more source